Mounjaro KwikPen 7.5mg is a high-affinity dual agonist for glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors. The active molecule, Tirzepatide, facilitates advanced glycemic control and metabolic optimization by enhancing insulin biosynthesis and inducing satiety.

Dosage & Administration

• Dosage: Adhere strictly to the dosing schedule and administration instructions provided by your physician.
• Method: Subcutaneous injection into the abdomen, thigh, or upper arm.
• Site Rotation: Rotate injection sites with each weekly dose to minimize tissue irritation.
• Cycle: One KwikPen contains 4 fixed doses (one month supply).
• Missed Dose Protocol: Administer a missed dose within 4 days of the scheduled date. If more than 4 days have elapsed, the missed dose should be omitted. It should be resumed on their usual schedule day. The interval between two consecutive doses must not be less than 72 hours.

Technical Specification

• Product Form: Multi-dose pre-filled KwikPen.
• Concentration: 7.5mg Tirzepatide per dose.
• Active Ingredient: Tirzepatide (synthetic peptide).
• Inactive Ingredients: Sodium chloride, sodium phosphate dibasic heptahydrate, and water for injection.

Ingredient Functionality

• Dual Incretin Mimetic: Tirzepatide acts as a unimolecular agonist at both GIP and GLP-1 receptors, providing superior glucose lowering compared to selective GLP-1 agonists.
• Pancreatic Response: Stimulates insulin secretion from pancreatic beta cells in a glucose-dependent mechanism.
• Glucagon Suppression: Decreases inappropriate glucagon secretion from alpha cells during hyperglycemic states.
• Gastric Kinetics: Decelerates the rate of gastric emptying, extending the duration of post-prandial nutrient absorption and satiety signaling.

Safety & Storage

• Temperature Control: Maintain refrigeration between 2°C and 8°C. Do not subject to freezing temperatures.
• Ambient Storage: The KwikPen remains stable at room temperature (up to 25°C) for a maximum of 21 days.
• Device Disposal: The pen must be discarded 28 days after the first dose is administered.
• Visual Inspection: Solution must be clear and colorless to slightly yellow; discard if particles or cloudiness are present.
• Compatible needles are required for administration; not included in this package.